Novartis funds app to boost Xolair in hives

Xolair

Xolair-maker Novartis wants to create a support community for patients with chronic urticaria, or hives. And it’s funding a new mobile app and website to do it.

The platform, dubbed TARGET My Hives, allows urticaria patients to digitally connect with one another, PMLiVE’s digital intelligence blog reports--but it’s not just for patients alone. It also allows doctors who treat the condition to register their information, making it easier for patients to find them.

The Swiss drugmaker also wants to bring in patient associations and medical societies; eventually, it plans for the app to allow sufferers to follow those associations and participate in real-world research in conjunction with their doctors.

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

There’s plenty of reason for Novartis’ interest in bringing the urticaria community together. The company has been working to broaden the reach of Xolair, which it markets outside the U.S.; that med, which treats the skin condition in addition to severe asthma, brought in $755 million last year.

TARGET My Hives isn’t Novartis’ first effort to do so, either. Back in 2014, the company teamed up with pro photographer Rick Guidotti to launch “Skin Impressions,” a campaign meant to inspire patients to “rediscover their confidence and the freedom to touch, hug and embrace their loved ones, empowering them to strive for a skin they can truly live in." That effort featured 14 "#SkinImpressions Ambassadors" from around the world who shared their stories through images, print and YouTube interviews.

Now isn’t a bad time for Novartis to increase up its efforts behind Xolair in hives, either, considering that the drug has some new, more targeted competition in severe asthma, its original indication. Late last year, GlaxoSmithKline won EC and FDA approval for Nucala, a product that addresses asthma with eosinophilic inflammation; that condition affects 60% of severe asthma patients, GSK says.

- get more from PMLiVE

Special Report: The top 15 pharma companies by 2014 revenue - Novartis

Related Articles:
GSK readies respiratory sales force to challenge Xolair in severe asthma​
Novartis taps hives and psoriasis patients for inspiration in dermatology campaign​
Novartis says asthma blockbuster Xolair also effective against serious hives

Read more on

Suggested Articles

Novartis is doing more portfolio pruning, offloading three endocrine drugs to Recordati.

Turns out, the FDA’s March rejection of Sanofi's Zynquista was just a preview of what would come for the SGLT class in Type 1 diabetes.

Indoco Remedies is not just getting the once over by the FDA but the twice-over as inspectors work through its plants and citations rain down.